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Breast cancer has the highest incidence rate of any cancer in the United States, and it is 
the second most deadly. It comprises 30% of all diagnosed cancers in women, and it is predicted 
that the incidence of breast cancer will continue to rise. Most common chemotherapeutic agents 
utilized in the treatment of breast cancer are known to be cardiotoxic, each with differing 
mechanisms and possible damage done to the patient. In turn, cardiovascular diseases are the 
number one killer of women in the United States, and their prevalence is continually growing. It 
is unknown exactly how many women who are treated with chemotherapeutic agents and survive 
breast cancer develop cardiovascular complications, and there is no predictive model to assist 
with discerning the patients who would be affected by this complication. The following is a 
review of literature that was conducted to determine the potential impact of utilizing the cardiac 
biomarkers C-reactive protein (CRP), homocysteine, brain natriuretic peptide (BNP), lipid 
profiles, and cardiac troponins as predictors of increased cardiovascular risk in women who 
require or have required chemotherapeutic treatment for breast cancer and to potentially establish 
a route to determining prevalence. This was completed by reviewing PubMed; Surveillance, 
Epidemiology, and End Results Program (SEER) databases; National Institutes of Health (NIH) 
reports; Tennessee Cancer Registry; Baroness Erlanger Hospital registry abstracting; and 
National Cancer Institute (NCI) reports. It was found that, with diligent monitoring, all the 
biomarkers studied could be used to quantify the women affected by cardiovascular disease 
(CVD) due to breast cancer treatment as well as to predict CVD in breast cancer patients to 






 In the United States alone, 276,480 new cases of breast cancer will be diagnosed in 2020; 
it is predicted that this number will continue to rise (“How Common”). Breast cancer comprises 
30% of all diagnosed cancers in women. It is the most common form of cancer and the second 
most deadly, behind lung cancer. Currently, the two most common forms of treatment for breast 
cancer are surgical removal (mastectomies) and chemotherapy, respectively (“How Common”). 
Some of the most common chemotherapeutic agents used to treat breast cancer are 
anthracyclines, trastuzumab, 5-fluorouracil, taxanes, cyclophosphamide, carboplatin, and 
vinorelbine. Of these, all are known to be cardiotoxic except carboplatin. Some of these agents 
are more damaging to the heart than others, and they each cause different problems in the 
cardiovascular system.  
 Anthracyclines result in damage to the mitochondria, disrupt ATP production, increase 
production of free radicals that affect cellular membranes, and induce apoptosis in healthy cells. 
This has led to many cardiovascular manifestations including left ventricular dysfunction (LVD), 
heart failure, myocarditis, and arrhythmias (Schwartz, et al. 1109; Zhou, et al. 771). Trastuzumab 
affects oncoprotein receptors, specifically ErbB2, expressed on the myocardium; it has been 
shown to cause LVD, heart failure, and arrhythmias (Crone, et al. 460; Park, et al.). 5-
fluorouracil is toxic to the vascular endothelium that leads to spasms of the arteries resulting in 
vasoconstriction. This agent may lead to ischemia, heart failure, pericarditis, and cardiogenic 
shock (Lieutaud, et al. 368). Taxanes, antimicrotubular drugs, damage the myocardium through 
effects on subcellular organelles or by causing a histamine release. They may cause sinus 
bradycardia, ventricular tachycardia, atrioventricular blocks, heart failure, and ischemia 
(Rowinsky, et al. 1704). The mechanisms for cardiotoxicity of cyclophosphamide is not known, 
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but it is hypothesized that it causes oxidative stress, damage to capillaries, and breakdown of 
endothelial cells (Dhesi, et al. 2); it also causes heart failure (resulting in neurohumoral 
activation) and mitral regurgitation (Zver, et al. 413). Again, the mechanisms for toxicity for 
vinorelbine are unknown, but it is hypothesized that the alkaloids from the drug affect 
microtubules in cells, impact the metabolism of myocardial cells, or cause issues with 
coagulation mechanisms. It has been shown to cause myocardial infarctions, pulmonary edema, 
and arrhythmias (Lapeyre-Mestre, et al. 97). 
 Although these drugs are known to be cardiotoxic, they are preferred for the treatment of 
breast cancer due to their overall effectiveness. Many of these drugs are used in conjunction with 
one another to enhance the effects, increase the survival rate, and lower the recurrence rate. 
Success rates for these drugs vary by patient, stage of breast cancer, dosage, and time 
administered. The most popularly used drugs, like anthracyclines, have been at the forefront of 
chemotherapeutic treatment of breast cancer for decades (Shah and Gradishar 1153); this makes 
them more trusted chemotherapeutic agents. Although there are new developments in breast 
cancer treatment, these chemotherapy drugs are the most time-tested agents with high success 
rates.  
Cardiovascular disease (CVD) consists of a variety of conditions such as atrial 
fibrillation, which results in altered electrical systems in the heart which affects rhythm and rate; 
coronary artery disease, in which the arteries and vessels narrow and can become blocked; 
congestive heart failure, in which the heart cannot pump enough blood to organs; high blood 
pressure, which increases pressure on the vascular system and the work required of the heart; 
strokes, which disrupt blood flow to the brain and can cause altered mental status and reduced 
limb function; and many other heart, cerebrovascular, and peripheral artery diseases (Virani, et 
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al. 333). The risk of CVD increases due to smoking, obesity, family history, poor diet, and lack 
of exercise. CVD accounts for roughly one third of all deaths worldwide; it has been the number 
one killer in the United States since 1920. By 2035, it is predicted that 45.1% of the population 
of the United States will have some form of CVD (Virani, et al. 337). A study in 2019 by Abdel-
Qadir et al., found that, compared to cancer-free women in the same age categories, breast cancer 
patients had a significantly higher risk of hospitalization due to CVD within 10 years of 
treatment. The hazard ratios, the probability of a cardiovascular event occurring in the 
cardiotoxic treatment group compared to the age-matched control groups, show the relative 
increase in risk of developing cardiovascular complications from treatment. The data for heart 
failure was found to have a hazard ratio of 1.69; this means that women being treated with 
cardiotoxic drugs are 69% more likely to develop heart failure than age-matched, cancer-free 
women. Similarly, the data for arrhythmias showed a 93% increase in risk for women being 
treated with cardiotoxic drugs. Additionally, this study found that, on average, women treated 
with anthracyclines and/or trastuzumab were having cardiac issues much earlier, in some cases 
10 years earlier, than the cancer-free women.  
Although it is known that cardiotoxic drugs can lead to a variety of cardiovascular 
problems throughout the patient’s life, it is unknown exactly how many women who survive 
breast cancer develop cardiovascular complications. Given the known cardiotoxicity of many 
common chemotherapeutic drugs for breast cancer treatment and the risk they pose for women’s 
cardiovascular health, there is a need to quantify the total number of women affected and identify 
those at highest risk prior to treatment in order to allow opportunity for providers to choose the 
best overall treatment option. This research emphasizes the need for the addition of biomarkers 
in monitoring cardiac health before, during, and after treatment of patients with 
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chemotherapeutic drugs. Addition of this data to the SEER database abstracting would 
standardize the data being collected as well as compel collection of biomarker data from multiple 
time periods during the treatment process. This would allow for interpretation and utilization of 
this data for the development of predictive protocol for the determination of cardiovascular 
complications in breast cancer patients using biomarkers. A review of literature was conducted to 
determine the potential impact of utilization of the cardiac biomarkers C-reactive protein (CRP), 
homocysteine, brain natriuretic peptide (BNP), lipid profiles, and cardiac troponins as predictors 
of increased cardiovascular risk in women who require or have required treatment for breast 
cancer and to potentially establish a route to determining prevalence through implementation of 
biomarker testing.  
 
Discussion 
After a review of the literature in PubMed, SEER, NIH, Tennessee Cancer Registry, 
Baroness Erlanger Hospital registry abstracting, and NCI, there was no routinely followed 
regimen for the monitoring of cardiac biomarkers in breast cancer patients. The purpose of this 
research is to outline the importance of cardiac biomarkers in the prevention and treatment of 
cardiovascular complications in breast cancer patients. The biomarkers of interest are linked to 
CVD in breast cancer patients, but they are not elements on SEER registry data for the research 
studies currently being conducted. Additionally, the studies confirming linkages between these 
biomarkers and CVD, such as those by Clos, Ganguly and Alam, Harvard Health Publishing, and 
Sharma, et al, did not utilize them as predictive elements in preventative awareness for breast 
cancer patients. This lack of unified data prevents the development of further research to use as 
possible predictive elements or markers of damage.  
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The SEER database is a program through the National Cancer Institute (NCI) which 
collects data from cancer registries throughout the United States. This information is routinely 
collected and updated. The data collected is submitted using a comprehensive registry 
application. Making biomarkers items on the registry application for SEER would homogenize 
the data being collected by individual studies and allow the data to be used in larger studies. 
Also, forced inclusion of this data would make providers collect data before and during treatment 
which allows for a more informed, adaptable approach to treatment. With more data, researchers 
have the potential to develop more accurate protocols for the determination of cardiovascular 
health in breast cancer patients.  
In addition, since there is an experimentally demonstrated link between the biomarkers of 
interest and CVD, these biomarkers, if monitored, could be used to assess cardiovascular health 
in breast cancer patients before, during, and after chemotherapy administration. Each biomarker 
should signal different events or risks in the patient.  Further, each biomarker presents with 
varying applicability as an indicator for cardiovascular health due to the differing signals 
interpreted in each test; some signals are not present before an event occurs, thus making it 
incapable of predicting an event. The applicability of the biomarker relies on its ability to detect 
changes in the patient that are a sign of or a precursor to cardiovascular damage.  
C-Reactive Protein (CRP) is a protein made by the liver in humans as a response to 
inflammatory cytokines in all areas of the body but primarily in arteries. Inflammation of cardiac 
tissue suggests an increased risk for a myocardial infarction (MI) or stroke. CRP acts as a 
surveillance molecule for changes in somatic cells as well as foreign molecules and is important 
in signaling and activating the immune responses. It binds to damaged tissue or pathogens and 
activates complements (Clos 275). The complement system is a response of the innate immune 
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system in which complement proteins help improve the effectiveness of antibodies and 
phagocytes. This process helps the immune cells attack and remove pathogens, as well as 
increase inflammation in the area (“The Complement System” 60). When injured, blood vessels 
create an inflammatory response which seals molecules with a collagen cap to prevent further 
damage to the blood vessel. Eventually, the deposit bursts open because of degradation by the 
immune response, releasing plaque and creating clots; this leads to blocked arteries or MIs. CRP 
is a highly sensitive indicator of the inflammatory response created by the body; there are 
multiple studies correlating high CRP levels with an increased chance of an MI. These studies 
are outlined in articles by Shomanova et al., Clos, and Harvard Health Publishing. The high 
sensitivity-CRP (hs-CRP) test, as opposed to a non-specific CRP test, is commonly used to 
evaluate the risk of a patient developing coronary artery disease because it indicates a narrowing 
of arteries, instead of just a general inflammatory response detected in non-specific CRP tests. 
However, the CRP test alone may be less accurate in predicting a cardiac event in some patients 
because of inflammation caused by arthritis, trauma, or other health issues elsewhere in the body 
(Harvard Health). Lee, et al. found in a study of 80,781 hospital patients that hs-CRP levels were 
consistently higher in cancer patients as opposed to patients without cancer, with the average hs-
CRP level being 1.5 mg/L higher. In patients with inflammatory disorders, including cancer 
patients, CRP levels can be chronically high, so baseline numbers of CRP should be used to 
detect differences from the patient’s normal levels. Overall, CRP is an effective biomarker in 
predicting a cardiovascular event because it suggests inflammation which could result in an MI; 




Homocysteine is an amino acid found in blood plasma that is formed as an intermediate 
during the metabolism of methionine to cysteine. All organs of the body have homocysteine, but 
it is primarily found in the kidneys and liver where it is used in protein synthesis. The presence 
of an abnormally high level of homocysteine is known as hyperhomocysteinemia. This condition 
can develop from genetic abnormalities in the metabolism of homocysteine, nutritional 
deficiencies, lack of vitamin B, and exposures to disease, drugs, alcohol usage, and tobacco 
usage. A strong correlation between this condition and cardiovascular disease has been shown 
through many studies, and elevated homocysteine levels have been shown to increase the risk of 
CVD (Ganguly and Alam 4; Shenoy et al., 339). The methods by which high homocysteine is 
thought to increase the risk of CVD include an increase in the synthesis of vascular smooth 
muscle cells, endothelial dysfunction, oxidative damage, increased production of collagen, and 
the breakdown of arterial walls. Homocysteine has also been linked with arteriosclerosis that 
leads to an increased amount of work required by the heart to pump blood throughout the body; 
this overworking can eventually lead to heart failure (Ganguly and Alam 5). A study by Shenoy 
et. al. showed homocysteine as an atherosclerotic promoter, that is, a link between homocysteine 
and the development of atherosclerosis was observed. In this study, fasting homocysteine levels 
were significantly higher in patients with coronary artery disease than those without (Shenoy, et 
al. 342). Therefore, homocysteine can be used as a predictor of cardiovascular disease because it 
is shown to be elevated in patients with conditions proven to lead to CVD. This is an important 
biomarker for monitoring cardiovascular health and preventative care for patients at risk of 
developing CVD due to chemotherapy.  
Brain Natriuretic Peptide (BNP) is a peptide hormone synthesized in the atria and 
ventricles. It is released upon stretching or expansion of the walls of the atria and ventricles 
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which is often due to increased blood volume. BNP promotes diuresis, natriuresis, and 
vasodilation. In multiple studies, it has shown to be produced during heart failure, MI, or in the 
presence of cardiomyopathies (Morita, et al. 88; Shomanova, et al. 3). Skovgaard, et al. found a 
moderate increase in BNP during chemotherapy treatment with this increase being irreversible in 
some patients. In the study of 333 observed patients, 21 were admitted for congestive heart 
failure (CHF). 79% of the patients admitted for CHF had high (>30 pg/mL) BNP levels. The 
authors concluded that BNP in conjunction with left ventricular ejection fraction (LVEF) are 
accurate predictors of cardiac impairment (Skovgaard, et al. 9). Shomanova, et al. suggest that it 
can be used in detection of cardiac impairment. Maisel, et al. establishes BNP as a useful 
predictor of short-term outcomes and the diagnosis of HF. If monitoring data is made more 
uniform, the amount of BNP that signals cardiac danger could be identified, and the accuracy of 
BNP as a predictor or as an aid in the diagnosis of heart failure and cardiomyopathies could be 
confirmed.  
Lipid profiles analyze the levels of total cholesterol in the blood. Cholesterol is made of 
high-density lipoproteins (HDL), triglycerides, and low-density lipoproteins (LDL). Cholesterol 
is necessary fat, as it stabilizes outer membranes of cells; however, high cholesterol levels are 
known to lead to CVD. LDL is known as “bad” cholesterol because it can stick to vessel walls, 
forming plaque that can ultimately clog the vessels; this build-up is called atherosclerosis. LDL 
can cause blood clots which ultimately could lead to MIs or strokes (Harvard Health). There is a 
known correlation between LDL and CVD, as patients with hyperlipidemia have approximately 
twice the risk of developing CVD compared to those with normal levels (Ibrahim and Jialal). 
This suggests that LDL is an indicating factor for CVD or other cardiovascular events. However, 
only about 50% of people who have an MI have high LDL levels (Harvard Health). This 
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suggests that the accuracy of LDL testing as a predictive tool for cardiac events could be 
successful, but in a limited capacity. According to the CDC, 26.2% of women used prescription 
medication to lower LDL levels, and the trend shows that this number is increasing. From 2013-
2016, on average, 12.9% of women in the United States over 20 years old had high cholesterol 
levels; this percentage increases to 18.6% when only considering the age category of  45-64 
years (National Center). Also, more than 70% of adults with diagnosed CVD take these 
medications to lower LDL levels to improve their CVD (“Products – Data Briefs”). On average, 
certain medications reduce LDL levels up to 60% depending on the form taken, however it is 
important to note that risk factors such as diet, age, smoking, or family history impact 
effectiveness (Nelson 197). It is not clear exactly how many of these patients continue to have 
CVD related issues such as an MI. An article by the Cleveland Clinic discusses that studies have 
shown that these drugs can positively affect atherosclerosis in patients with CVD. Additionally, 
the Jupiter Trial project on patients with high risk of CVD found that, when compared to a 
placebo, patients on medication to lower LDL levels had an approximately 54% lower chance of 
an MI and a 46% lower chance of needing a coronary artery bypass (CABG) or an angioplasty, 
two surgeries to treat blockages in the heart or blood vessels (Ridker, P. et al. 2201). Given this 
information, LDL could be valuable as a CVD predictor due to its indication of vessel damage 
and clotting which can ultimately lead to MI. This biomarker, with more uniform data, could be 
more accurately analyzed to determine the success rates of its predictive capabilities. 
 Cardiac troponins are proteins found in the muscle fibers of cardiac tissue that regulate 
muscular contraction and the calcium mediated interactions between actin and myosin. They 
have not been identified outside of the heart, which allows for an accurate depiction of what is 
occurring in the heart and increases the specificity of the marker. Tests for cardiac troponins can 
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detect injury to the heart because they are released into the blood when damage to the heart 
occurs. Cardiac troponins are most commonly used to detect when an MI has occurred in a 
patient. However, they can also be used to identify patients at high risk for a cardiac event or 
CVD (Sharma, et al. 1025). Since troponin levels are very sensitive, they have been shown to 
slightly increase when a patient has cancer and increase more when treatment begins. They have 
been shown to increase significantly with escalating or prolonged treatment. This is due to the 
increased stress on the heart because of weakened heart muscles, cardiovascular apoptosis, and 
blood vessels due to oxidative stress developed by the production of free radicals while 
undergoing chemotherapy. Free radicals result in an influx and build-up of calcium, degradation 
of myocytes, and mitochondrial dysfunction. This damage is a side effect of most 
chemotherapeutic drugs, but it is most commonly reported in anthracyclines (Quryshi, et al. 11). 
There is also experimental indication confirmed by echocardiography that increasingly abnormal 
troponin levels directly reflect diminishing LVF. Timing of administration of cardiac troponin 
testing may be key in determining damage done to the heart; Cardinale, et al. found that in the 63 
patients with consistently increasing cardiac troponin levels within the month after treatment had 
an 84% incidence rate of a cardiovascular event within three years of completing treatment. The 
145 patients that had high troponin levels within the first three days after each chemotherapy 
treatment but reduced values a month after treatment had a cardiovascular incidence rate of 37%. 
Highly sensitive cardiac troponin tests can detect minute amounts of troponins and monitoring 
the changes in these small amounts was shown to be useful in the prediction of cardiovascular 
complications (Sawaya, et al.). A study by Ky, et al. in 2014 showed the predictive power of 
troponins by monitoring cardiac troponin levels in patients every three months for a total of 
fifteen months. These patients were being treated with doxorubicin and trastuzumab. A 
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significant average increase of 13.9 ng/L was found between the baseline troponin levels and the 
levels at the patient’s second visit three months after the baseline was taken. The researchers 
found that a statistically significant increase in the number of cardiac troponins from the baseline 
levels to levels after treatment was an accurate predictor of cardiac dysfunction. The hazard ratio 
predicting the cardiotoxicity for patients with increasing troponins was found to be 1.38, 
indicating a 38% increased risk. Cardiac troponins are some of the most tested and effective 
biomarkers directly related to the risk of CVD. Cardiac troponin testing could be used in 
decision-making for enhanced preventative measures for CVD if correctly timed because of its 
ability to detect not just damage but myocardial stress without damage. This testing timeline 
would have to be experimentally developed by determining the timing of the most accurate test 
results. Routine testing of patients at different points throughout their treatment would allow for 
more accurate predictive data. The updated registry submitted data in a SEER database could 
decrease the time needed to determine an accurate timeline for predictive monitoring of patients 
due to the amount of data reported simultaneously by multiple ongoing research projects.   
 All the biomarkers of interest can be tested through common blood tests. Some of these 
biomarker levels are not tested before a cardiovascular event for preventative measure; rather, 
they are often taken during or after a suspected cardiovascular event to confirm it or to diagnose 
patients with cardiac disorders. These tests are seldom run on breast cancer patients. However, 
lipid profiles are commonly tested in many patients, and homocysteine testing is being used 
more often on patients with risk factors. The usage of a SEER database to increase and 
homogenize the data from these biomarkers in breast cancer patients could result in the 
development of predictive protocol to prevent CVD in breast cancer patients.  
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The cost of the biomarker tests is significantly less than the cost of CVD or 
cardiovascular events. Biomarker testing often costs less than $100. For example, according to 
Harvard Health Publishing, the CRP test costs between $12 and $16, but there are always 
discrepancies with the cost of medical procedures due to hospital, governmental, and insurance 
fees (figure 1). Medical costs for CVD are the highest medical costs for any disease, accounting 
for 14% of the United States’ total medical expenditures from 2014-2015. The total cost of CVD 
in the United States is projected to increase from the 2015 direct medical cost of $318 billion to 
$749 billion by 2035 (Virani, et al. 337; figure 2). For example, in a study performed by Kilgore, 
et al. in 2017, the mean per-patient cost of a cardiovascular related hospitalization without a 
procedure involved was $16,000 with 40.2% of patients being readmitted within 90 days. Data 
from Giacomino, et al. gives the average value for a CABG procedure in the United States in 
2016 as $151,271. This cost is high because of the extended hospital stay required with this 
difficult procedure; additionally, this procedure occasionally results in complications and follow 
up-costs. On average, an angioplasty and placement of a stent to clear a clogged artery, is 
$49,245 (Sen, et al. 210). The cost-benefit analysis of preventative testing measures versus 





Figure 1: This figure outlines the medical costs of CVD related procedures, non-procedure 
related CVD hospitalization, and biomarker test prices (Giacomino, et al. 1103; Harvard Health 
Publishing; Kilgore, et al. 63; Sen, et al. 210). The investment of time, resources, and money into 
biomarker testing lessens the risk of more serious, expensive, life-threatening procedures through 
























Figure 2: This figure outlines a cost breakdown for CVDs showing an increase in cost through 
2035 (Virani, et. al. 337). CVD indicates cardiovascular disease; HBP, high blood pressure; 
CHD, coronary heart disease; and CHF, congestive heart failure. This data shows how significant 
the increase in cost is for CVD in the United States. This increase in cost will continue to 
increase as the relevance of CVD increases.  
 
 The field of cardio-oncology is new, and the growth of practice and research in this field 
provides a promising future for cancer patients experiencing the cardiotoxic effects of cancer 
treatment. Using preventative measures such as monitoring biomarkers has promise in changing 
the outlook of treatment for female breast cancer patients, as it offers a way to individualize and 
adapt treatment to minimize cardiovascular damage in every patient. Monitoring of biomarkers 
that signal cardiovascular damage will allow medical professionals to understand how their 
patient is being affected by the treatment, and it gives them time to alter the treatment plan to 
safely reduce the damage being done while still successfully treating the cancer. There are many 
strategies and pharmacological approaches to the reduction of cardiovascular damage in patients 
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receiving chemotherapy. Cardioprotective drugs, adjustments in chemotherapy administration 
timelines, changes in chemotherapy agents used, and many other techniques have shown promise 
in managing cardiovascular damage if administered early in the treatment process. Studies such 
as the Cardiac CARE trial are attempting to determine the effectiveness of different treatment 
options to reduce cardiovascular damage (MacLean).  
 Clinical application of biomarkers as possible predictive tools for CVD in breast cancer 
patients has yet to be established on a large scale. Exact timelines for biomarker testing 
administration can be developed upon further experimentation and normalization of protocol 
outside of controlled trials through collaborative usage of SEER databases and the determination 
of the most accurate results. The methodology of experiments reviewing biomarker levels in 
cancer patients already completed or in progress have similar timelines for testing their patients. 
First, a baseline is taken before beginning the administration of treatment; then, readings are 
taken soon after the first administration to obtain a baseline of treatment levels. Next, the 
biomarker levels are retaken every 3-5 months throughout treatment. Depending on the study, 
patients were monitored up to three years after termination of treatment to track biomarker levels 
(Sawaya, et al.; Ky, et al. 811; Garrone, et al. 136). Patients with increased risk of CVD should 
have more frequent testing to more closely monitor their cardiac health. An example of an 
experimental timeline tracking biomarker levels and cardiac impairment throughout breast 





Figure 3: Outlines suggested course of study for administration of questionnaire of cardiac 
health, an echocardiogram, and blood biomarker testing at various points during treatment 
(Sawaya, et al.).  
 
 Based on the results of this review, high sensitivity cardiac troponins show the most 
promise as a predictive tool for the detection and prevention of CVD in breast cancer patients. 
However, CRP, homocysteine, BNP, and lipid profiles could potentially serve as predictive 
biomarkers as well. These biomarkers could be less accurate as a result of interference from 
other bodily functions, such as inflammation due to chemotherapy. However, with more 
extensive research and the development of an accurate timeline of testing, these biomarkers 
could be useful as predictors of CVD.  
  
Limitations  
This study was limited by access to databases that are private or non-disclosed to the 
public. These databases could possibly contain relevant information to this study, but they were 
unable to be analyzed for this purpose. Only information that is publicly available was used. 
There was no funding for this project, so the development of patient testing models was not 
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possible. Therefore, this study could not conduct trials on patients. Additionally, this study was 
limited to the biomarkers with known linkage to cardiotoxicity. There may be other biomarkers 
better suited for this study that have yet to be discovered or published.  
 
Conclusion  
Biomarkers present exciting potential for monitoring chemotherapeutic agent related 
cardiotoxicity and would allow for quantification of the number of women affected by the 
cardiotoxicity of the drugs used. They would also offer the opportunity to provide prevention or 
cessation of any potential or actual cardiac damage. Since these biomarkers are not being 
routinely monitored, the addition of cardiac biomarkers in the registry application for a database 
such as SEER would increase the amount of data, quality of predictive mechanisms, and 
relevance of preventative treatment. All the biomarkers outlined in this review can be used to 
identify the women treated for breast cancer who develop cardiovascular complications such as 
CVD. The biomarkers CRP, homocysteine, lipid profiles, and cardiac troponins show the most 
promise of being used as markers to guide preventative care for women if they are correctly 
monitored. However, each biomarker has varying levels of accuracy. Changes in these 
biomarkers are indicative of worsening cardiac health and can be used to predict future 
cardiovascular events. This would create an opportunity for an adjusted plan of treatment to 






Future Research  
Further research and implementation of these predictive measures is important. A 
machine learning algorithm could be used to offer a more individualized breast cancer treatment 
plan after training it with known patient data and outcomes. Other possible predictors or 




 I would like to thank Professor Laurel Rhyne and Dr. Shirleen Chase for their support, 
guidance, patience, encouragement, and positivity throughout the duration of this project. Also, I 
would like to thank my thesis committee members, Dr. David Giles and Professor Katherine 
Harrell, for their guidance and support. Finally, a huge thank you to my family and friends for 
their unwavering support and love.  
 
References  
Abdel-Qadir, Husam, et al. “The Risk of Heart Failure and Other Cardiovascular 
Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.” JNCI: 




Cardinale, Daniela, et al. “Prognostic Value of Troponin I in Cardiac Risk Stratification of 
Cancer Patients Undergoing High-Dose Chemotherapy.” Circulation, vol. 109, no. 22, 8 
June 2004, pp. 2749–2754., doi:10.1161/01.CIR.0000130926.51766.CC.  
Clos, Terry W Du. “Function of C-Reactive Protein.” Annals of Medicine, vol. 32, no. 4, 8 July 
2009, pp. 274–278., doi:10.3109/07853890009011772.  
Crone, Steven A., et al. “ErbB2 Is Essential in the Prevention of Dilated Cardiomyopathy.” 
Nature Medicine, vol. 8, no. 5, 1 May 2002, pp. 459–465., doi:10.1038/nm0502-459.  
Dhesi, Sumandeep, et al. “Cyclophosphamide-Induced Cardiomyopathy.” Journal of 
Investigative Medicine High Impact Case Reports, vol. 1, no. 1, 1 Jan. 2013, pp. 1–7., 
doi:10.1177/2324709613480346.  
Ganguly, Paul, and Sreyoshi Fatima Alam. “Role of Homocysteine in the Development of 
Cardiovascular Disease.” Nutrition Journal, vol. 14, no. 6, 10 Jan. 2015, pp. 1–10., 
doi:10.1186/1475-2891-14-6.  
Garrone, Ornella, et al. “Prediction of Anthracycline Cardiotoxicity after Chemotherapy by 
Biomarkers Kinetic Analysis.” Cardiovascular Toxicology, vol. 12, no. 2, 22 Dec. 2011, 
pp. 135–142., doi:10.1007/s12012-011-9149-4.  
Giacomino, Bria D., et al. “Association of Hospital Prices for Coronary Artery Bypass Grafting 
With Hospital Quality and Reimbursement.” The American Journal of Cardiology, vol. 
117, no. 7, 1 Apr. 2016, pp. 1101–1106., doi:10.1016/j.amjcard.2016.01.004.  
21 
 
Harvard Health Publishing. “C-Reactive Protein Test to Screen for Heart Disease: Why Do We 
Need Another Test?” Harvard Health, 21 Mar. 2017, www.health.harvard.edu/heart-
health/c-reactive-protein-test-to-screen-for-heart-disease. 
“How Common Is Breast Cancer?: Breast Cancer Statistics.” American Cancer Society, Sept. 
2019, www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html.  
Ibrahim, Michael A., and Ishwarlal Jailal. “Hypercholesterolemia.” StatPearls Publishing, 30 
Oct. 2017, https://www.ncbi.nlm.nih.gov/books/NBK459188/.  
Kilgore, Meredith, et al. “Economic Burden of Hospitalizations of Medicare Beneficiaries with 
Heart Failure.” Risk Management and Healthcare Policy, vol. 10, 10 May 2017, pp. 63–
70., doi:10.2147/rmhp.s130341. 
Ky, Bonnie, et al. “Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in 
Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab.” 
Journal of the American College of Cardiology, vol. 63, no. 8, 4 Mar. 2014, pp. 809–
816., doi:10.1016/j.jacc.2013.10.061. 
Lapeyre-Mestre, Maryse, et al. “Vinorelbine-Related Cardiac Events: a Meta-Analysis of 
Randomized Clinical Trials.” Fundamental and Clinical Pharmacology, vol. 18, no. 1, 27 
Jan. 2004, pp. 97–105., doi:10.1046/j.0767-3981.2003.00215.x. 
Lee, Seounghee, et al. “High-Sensitivity C-Reactive Protein and Cancer.” Journal of 
Epidemiology, vol. 21, no. 3, 5 May 2011, pp. 161–168., doi:10.2188/jea.JE20100128.  
22 
 
Lieutaud, T., et al. “5-Fluorouracil Cardiotoxicity: A Unique Mechanism for Ischaemic 
Cardiopathy and Cardiac Failure?” European Journal of Cancer, vol. 32, no. 2, 1996, pp. 
368–369., doi:10.1016/0959-8049(95)00575-7. 
MacLean, Morag. “The Cardiac CARE Trial – Can Heart Muscle Injury Related to 
Chemotherapy Be Prevented?” ISRCTN, 5 May 2020, 
www.isrctn.com/ISRCTN24439460.  
Maisel, Alan S., et al. “Prognostic Utility of Plasma Neutrophil Gelatinase-Associated Lipocalin 
in Patients with Acute Heart Failure: The NGAL Evaluation Along with B-Type 
Natriuretic Peptide in Acutely Decompensated Heart Failure (GALLANT) Trial.” 
European Journal of Heart Failure, vol. 13, no. 8, 9 May 2011, pp. 846–851., 
doi:10.1093/eurjhf/hfr087.  
Morita, Etsuo, et al. “Increased Plasma Levels of Brain Natriuretic Peptide in Patients with 
Acute Myocardial Infarction.” Circulation, vol. 88, no. 1, July 1993, pp. 82–91., 
doi:10.1161/01.cir.88.1.82. 
National Center for Health Statistics. “HUS Trend Table 23. Cholesterol among adults aged 20 
and over, by selected characteristics: United States, selected years 1988–1994 through 
2013–2016.” Health, United States. 2018. https://www.cdc.gov/nchs/hus/index.htm 
Nelson, Robert H. “Hyperlipidemia as a Risk Factor for Cardiovascular Disease.” Primary Care: 




Park, J., et al. “Trastuzumab-Mediated Cardiac Dysfunction (CDx) Outside of Clinical Trials: 
Single Asian Center Experience.” Journal of Clinical Oncology, vol. 27, no. 15, 20 May 
2009, doi:10.1200/jco.2009.27.15_suppl.e20732.  
“Products - Data Briefs - Number 177 - December 2014.” Centers for Disease Control and 
Prevention, Centers for Disease Control and Prevention, 6 Nov. 2015, 
www.cdc.gov/nchs/products/databriefs/db177.htm. 
Quryshi, Nabeel, et al. “The Role of Telomerase to Counteract Mitochondrial Defects and 
Oxidative Stress.” International Journal of Molecular Sciences, vol. 19, no. 3, 10 Mar. 
2018, pp. 1–32., doi:10.3390/ijms19030797.  
Ridker, Paul M., et al. “Rosuvastatin to Prevent Vascular Events in Men and Women with 
Elevated C-Reactive Protein.” The New England Journal of Medicine, vol. 359, no. 21, 
20 Nov. 2008, pp. 2195–2207., doi:10.1056/NEJMoa0807646.  
Rowinsky, E K, et al. “Cardiac Disturbances during the Administration of Taxol.” Journal of 
Clinical Oncology, vol. 9, no. 9, Sept. 1991, pp. 1704–1712., 
doi:10.1200/jco.1991.9.9.1704.  
Sawaya, Heloisa, et al. “Assessment of Echocardiography and Biomarkers for the Extended 
Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and 
Trastuzumab.” Circulation: Cardiovascular Imaging, vol. 5, no. 5, Sept. 2012, pp. 596–
603., doi:10.1161/circimaging.112.973321. 
Schwartz, Ronald G., et al. “Congestive Heart Failure and Left Ventricular Dysfunction 
Complicating Doxorubicin Therapy.” The American Journal of Medicine, vol. 82, no. 6, 
1 June 1987, pp. 1109–1118., doi:10.1016/0002-9343(87)90212-9.  
24 
 
Sen, Shuvayu S., et al. “A One-Year Comparison of Cost and Outcomes of Angioplasty in Stent 
and Nonstent Patients.” American Journal of Therapeutics, vol. 12, no. 3, 2005, pp. 210–
217. PMID: 15891263. 
Shah, Ami N., and William J. Gradishar. “Adjuvant Anthracyclines in Breast Cancer: What Is 
Their Role?” The Oncologist, vol. 23, no. 10, 17 Aug. 2018, pp. 1153–1161., 
doi:10.1634/theoncologist.2017-0672.  
Sharma, S., et al. “Cardiac Troponins.” Journal of Clinical Pathology, vol. 57, 27 Sept. 2004, pp. 
1025–1026., doi:10.1136/jcp.2003.015420. 
Shenoy, Vijetha, et al. “Correlation of Serum Homocysteine Levels with the Severity of 
Coronary Artery Disease.” Indian Journal of Clinical Biochemistry, vol. 29, no. 3, 31 
Aug. 2013, pp. 339–344., doi:10.1007/s12291-013-0373-5. 
Shomanova, Zornitsa, et al. “Classic and Novel Biomarkers as Potential Predictors of Ventricular 
Arrhythmias and Sudden Cardiac Death.” Journal of Clinical Medicine, vol. 9, no. 2, 20 
Feb. 2020, pp. 1-29., doi:10.3390/jcm9020578. 
Skovgaard, Dorthe, et al. “BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: 
Comparison with Gated Equilibrium Radionuclide Ventriculography.” PLoS One, vol. 9, 
no. 5, 6 May 2014, pp. 1-10., doi:10.1371/journal.pone.0096736.  




“The Complement System and Innate Immunity.” Immunobiology: The Immune System in 
Health and Disease, by Charles A. Janeway et al., 5th ed., Garland Science, 2007, pp. 
60–83.  
Virani, Salim S., et al. “Heart Disease and Stroke Statistics—2020 Update: A Report From the 
American Heart Association.” Circulation, vol. 141, no. 9, 29 Jan. 2020, pp. 139–596., 
doi: 10.1161/CIR.0000000000000757. 
Zhou, Shaoyu, et al. “Cumulative and Irreversible Cardiac Mitochondrial Dysfunction Induced 
by Doxorubicin.” The Journal of Cancer Research, vol. 61, no. 2, 15 Jan. 2001, pp. 771–
777. PMID: 11212281. 
Zver, Samo, et al. “Cardiac Toxicity of High-Dose Cyclophosphamide in Patients with Multiple 
Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.” 
International Journal of Hematology, vol. 85, no. 5, 1 June 2007, pp. 408–414., 
doi:10.1532/ijh97.e0620. 
